CN105616490A - Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine - Google Patents
Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine Download PDFInfo
- Publication number
- CN105616490A CN105616490A CN201610087097.3A CN201610087097A CN105616490A CN 105616490 A CN105616490 A CN 105616490A CN 201610087097 A CN201610087097 A CN 201610087097A CN 105616490 A CN105616490 A CN 105616490A
- Authority
- CN
- China
- Prior art keywords
- flos carthami
- carthami extract
- salviae miltiorrhizae
- radix salviae
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An embodiment of the invention discloses application of Radix salvia miltiorrhiza Flos carthami extract in preparing medicine for treating and/or preventing vascular thrombotic diseases. The Radix salvia miltiorrhiza and Flos carthami extract is prepared by extracting Radix salvia miltiorrhiza and Flos carthami and can be prepared into tablets, capsules, soft capsules, pills, granules or injections, and the vascular and thrombotic diseases are diseases caused by artery thrombosis. The Radix salvia miltiorrhiza and Flos carthami extract can inhibit platelet aggregation, thereby being capable of effectively treating and/or preventing the vascular thrombotic diseases.
Description
Technical field
The present invention relates to field of traditional Chinese, particularly to Radix Salviae Miltiorrhizae Flos Carthami extract purposes in preparing medicine.
Background technology
Platelet is one of composition in mammalian, has important effect in the physiological process such as hemostasis. When blood vessel sustains damage due to reasons such as wounds, platelet assembles the agglomerating blood vessel blocking damage at the blood vessel place sustained damage, and reaches the purpose of hemostasis. Meanwhile, platelet also plays important effect in numerous disease. Platelet, under being subject to environmental stimuli, the stimulation of such as chemical factor, is activated in the blood vessel, assembles, and during lesser extent, blood viscosity can be made high, when degree is heavier, can produce thrombosis.
The vascular thrombosis class disease caused by platelet gathering in the blood vessel has become as a kind of frequently-occurring disease, commonly encountered diseases, for instance, when platelet is assembled in the artery, arterial thrombus can be caused, and arterial thrombus can cause acral necrosis, such as dry gangrene; When platelet is assembled in vein, phlebothrombosis can be caused, and then may result in the generation of wet gangrene; And when patient itself has diabetes, if the gathering that platelet is in the blood vessel so that when blood viscosity height even forms thrombosis, also can induced Diabetic foot generation.
Visible, when preventing and treating these diseases above-mentioned, it is critical that how can the hematoblastic gathering of antagonism.
Radix Salviae Miltiorrhizae Flos Carthami extract is by adopting certain mode to extract and make Radix Salviae Miltiorrhizae Flos Carthami, it is possible to blood circulation promoting and blood stasis dispelling, TONGMAI SHULUO. The traditional Chinese medical science is used for treating the breast fraud caused by blood stasis impatency and apoplexy. Clinic is usually used in treatment coronary heart diseases and angina pectoris, blood stasis type pulmonary heart disease etc.
Summary of the invention
Inventor find unexpectedly Radix Salviae Miltiorrhizae Flos Carthami extract can the hematoblastic gathering of antagonism, and complete the present invention based on this.
The invention discloses Radix Salviae Miltiorrhizae Flos Carthami extract purposes in the medicine of preparation treatment and/or prevention vascular thrombosis class disease.
In the preferred embodiment of the present invention, described vascular thrombosis class disease is the disease caused by arterial thrombus; In the another kind of preferred implementation of the present invention, the described disease caused by arterial thrombus is the acral downright bad class disease caused by arterial thrombus; In another preferred implementation of the present invention, the described disease caused by arterial thrombus is the dry gangrene caused by arterial thrombus.
In the preferred embodiment of the present invention, described vascular thrombosis class disease is wet gangrene or diabetic foot.
In the preferred embodiment of the present invention, described Radix Salviae Miltiorrhizae Flos Carthami extract is in the one in tablet, capsule, soft capsule, pill, granule or injection.
In the preferred embodiment of the present invention, described Radix Salviae Miltiorrhizae Flos Carthami extract is in the form of DANHONG ZHUSHEYE.
The invention discloses Radix Salviae Miltiorrhizae Flos Carthami extract purposes in preparing medicine. Due to Radix Salviae Miltiorrhizae Flos Carthami extract can the hematoblastic gathering of antagonism, therefore, Radix Salviae Miltiorrhizae Flos Carthami extract has treatment and/or the purposes of medicine of prevention vascular thrombosis class disease.
Accompanying drawing explanation
In order to be illustrated more clearly that the embodiment of the present invention or technical scheme of the prior art, the accompanying drawing used required in embodiment or description of the prior art will be briefly described below, apparently, accompanying drawing in the following describes is only some embodiments of the present invention, for those of ordinary skill in the art, under the premise not paying creative work, it is also possible to obtain other accompanying drawing according to these accompanying drawings.
Figure 1A is: add the platelet aggregation rate after variable concentrations DANHONG ZHUSHEYE and time chart;
Figure 1B is: add the maximum platelet aggregation rate after variable concentrations DANHONG ZHUSHEYE and DANHONG ZHUSHEYE dose curve figure;
Fig. 2 is: add the dose relationship figure that in the platelet after variable concentrations DANHONG ZHUSHEYE, adenosine cyclophosphate increment rate is injected with DANHONG;
Fig. 3 A is: adds the intracellular calcium concentration after variable concentrations DANHONG ZHUSHEYE and raises and time chart;
Fig. 3 B is: add the dose relationship figure of the cell energy calcium ion ultimate density after variable concentrations DANHONG ZHUSHEYE and DANHONG ZHUSHEYE;
Fig. 4 is: give the dose relationship figure of the residual of the Intravascular Thrombus after various dose DANHONG ZHUSHEYE and DANHONG ZHUSHEYE;
Fig. 5 is: give the dose relationship figure of the rat-tail dry gangrene lesion degree after various dose DANHONG ZHUSHEYE and DANHONG ZHUSHEYE.
Detailed description of the invention
Modern medicine shows, vascular thrombosis class disease is mainly caused by hematoblastic gathering. And hematoblastic gathering, it is owing to directly assembling under the stimulation causing poly-agent such as adenosine diphosphate (ADP) (ADP) on the one hand, on the other hand, cause poly-agent such as adenosine diphosphate (ADP) (ADP) by some chemical substances of affecting in platelet thus aggravating hematoblastic gathering, for instance ADP can cause in the rising of free calcium ion concentration in platelet kytoplasm and platelet the reduction of cyclic adenosine monophosphate (cAMP) to promote hematoblastic gathering.
The present inventor is found surprisingly that, Radix Salviae Miltiorrhizae Flos Carthami extract can suppress to cause the poly-agent such as ADP platelet aggregation caused as derivant on the one hand, cAMP concentration can reduce in the platelet that causes of antagonism ADP on the other hand, calcium ion concentration in the ADP platelet caused is suppressed to raise, thus suppressing platelet aggregation further, thus reaching to remove the effect of Intravascular Thrombus.
Therefore, the present invention relates to the use of the method that Radix Salviae Miltiorrhizae Flos Carthami extract is treated and/or prevented vascular thrombosis class disease, and and then provide Radix Salviae Miltiorrhizae Flos Carthami extract new application in the medicine of preparation treatment and/or prevention vascular thrombosis class disease.
Concrete, on the one hand, vascular thrombosis class disease can be the disease caused by arterial thrombus. The acral downright bad class disease such as caused by arterial thrombus. And the typical disease of the acral downright bad class disease caused by arterial thrombus is the dry gangrene caused by arterial thrombus. On the other hand, vascular thrombosis class disease, it is also possible to for: wet gangrene or diabetic foot.
It should be noted that Radix Salviae Miltiorrhizae Flos Carthami extract specifically described herein can be obtained through extraction by the flower of the Flos Carthami (CarthamustinctoriusL.) of the root and rhizome of the Radix Salviae Miltiorrhizae (SalviamiltiorrhizaBunge) of recipe quantity and recipe quantity. Its extracting method is known technology, and the present invention is not especially limited this. It is for instance possible to use extracting method described in the patent documentation that application number is 201010164957.1 prepares. Radix Salviae Miltiorrhizae Flos Carthami extract can also provide with the form of DANHONG ZHUSHEYE, for instance the DANHONG ZHUSHEYE of employing Heze Buchang Pharma Co., Ltd., lot number, and 13081025.
Utilizing Radix Salviae Miltiorrhizae Flos Carthami extract when preparing medicine, the dosage form of its prepared medicine can be the one in tablet, capsule, soft capsule, pill, granule, injection. In preparing the solid dosage formss such as tablet, capsule, soft capsule, pill, granule, Radix Salviae Miltiorrhizae Flos Carthami extract can accept excipient or carrier such as sodium citrate or dicalcium phosphate with the medicine of at least one inertia and/or following material mixes: a) filler or extender such as starch, lactose, sucrose, glucose, mannitol and silicic acid; B) binding agent such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and Radix Acaciae senegalis; C) wetting agent such as glycerol; D) disintegrating agent such as agar, calcium carbonate, Rhizoma Solani tuber osi or tapioca, alginic acid, some silicate and sodium carbonate; E) solution retarding agents such as paraffin; F) accelerator such as quaternary ammonium compound is absorbed; G) wetting agent such as spermol and glyceryl monostearate; H) adsorbent such as Kaolin and bentonite and i) lubricant such as Pulvis Talci, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulphate and their mixture. When capsule, tablet and pill, described dosage form also can comprise buffer agent. Liquid dosage form for oral administration includes pharmaceutically acceptable Emulsion, solution, suspensoid, syrup and elixir. Liquid dosage form is except containing also containing inert diluent commonly used in the art except Radix Salviae Miltiorrhizae Flos Carthami extract, such as water or other solvents, the fatty acid ester of solubilizing agent and emulsifying agent such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3 butylene glycol, dimethylformamide, oils (particularly Oleum Gossypii semen, Oleum Arachidis hypogaeae semen, Semen Maydis oil, germ oil, olive oil, Oleum Ricini and Oleum sesami), glycerol, oxolane alcohol, Polyethylene Glycol and sorbitan and their mixture.
Present invention also offers a kind for the treatment of and pre-vascular thrombosis class disease in experimenter in need, concrete, the acral downright bad class disease caused by arterial thrombus, more specifically, being the method for the dry gangrene caused by arterial thrombus, the method includes the Radix Salviae Miltiorrhizae Flos Carthami extract using effective dose to described experimenter.
As described herein, term " effective dose " refers to and can realize prevention in experimenter and treat the purpose dosage of disease of the present invention. Those skilled in the art are according to the context of the invention, it is possible to be readily determined the using dosage of Radix Salviae Miltiorrhizae Flos Carthami extract. Especially, this is according to the present invention, and term " effective dose " can be understood as the Radix Salviae Miltiorrhizae Flos Carthami extract q.s with the reasonable effect/Hazard ratio treatment obstacle suitable in any therapeutic treatment. It is to be understood that total consumption per day of Radix Salviae Miltiorrhizae Flos Carthami extract of the present invention can be maked decision within the scope of reliable medical judgment by those skilled in the art. For any concrete experimenter, concrete prevention effective dose level must be determined according to many factors, and described factor includes the age of experimenter, body weight, general health situation, sex and diet etc.
As described herein, term " experimenter ", be also referred to as " patient ", " user " that use this Radix Salviae Miltiorrhizae Flos Carthami extract etc., can refer to accept Radix Salviae Miltiorrhizae Flos Carthami extract of the present invention prevention and/or treat the animal of disease of the present invention, particularly mammal, for instance people, Canis familiaris L., monkey, cattle, horse etc.
Need further exist for illustrate be, various terms and phrase that the present invention uses have and well known to a person skilled in the art general sense, nonetheless, the present invention remains desirable at this, these terms and phrase are described in more detail and explained, the term mentioned and phrase, if any inconsistent with common art-recognized meanings, are as the criterion with the implication that the present invention states.
The present invention is further illustrated below by specific embodiment, it should be understood, however, that, these embodiments are only used for the use specifically described in more detail, and are not to be construed as limiting in any form the present invention.
The material that used and test method in test are carried out generality and/or concrete description by the present invention. Although for realize many materials that the object of the invention uses and operational approach is to it is known in the art that but the present invention remains in this to be described in detail as far as possible. It will be apparent to those skilled in the art that hereinafter, if not specified, material therefor of the present invention and operational approach are well known in the art.
The Radix Salviae Miltiorrhizae Flos Carthami extract adopted in following each enforcement is specifically provided by DANHONG ZHUSHEYE (Heze Buchang Pharma Co., Ltd., lot number: 13081025, the place of production: Heze City, Shandong Province). It is to say, Radix Salviae Miltiorrhizae Flos Carthami extract in employing DANHONG ZHUSHEYE is as the source of Radix Salviae Miltiorrhizae Flos Carthami extract. Certain those skilled in the art can also obtain Radix Salviae Miltiorrhizae Flos Carthami extract by other approach, for instance, adopt prior art to carry out extraction etc., the present invention is not especially limited at this. The Radix Salviae Miltiorrhizae Flos Carthami extract that other approach obtains is adopted to carry out following each embodiment, as long as dosage is converted to equivalent.
Embodiment 1: the inhibitory action of the platelet aggregation that ADP is caused by Radix Salviae Miltiorrhizae Flos Carthami extract
First take a blood sample from postanesthetic rat aorta, whole blood is mixed into the ACD solution (38mMcitricacid, 75mMsodiumcitrate, 124mMdextrose) of 10%. Then, use the centrifugal force of 200g, centrifugal 10 minutes, obtain the platelet rich plasma on upper strata. After extracting platelet rich plasma, then platelet rich plasma is centrifuged, centrifugal force 800g, centrifugal 10 minutes. Discard the platelet poor plasma on upper strata, add bufferA (130mMNaCl, 10mMsodiumcitrate, 9mMNaHCO3,6mMdextrose,0.9mMMgCl2,0.81mMKH2PO4, 10mMTris, pH7.35��7.45), and make platelet be resuspended in bufferA, obtain platelet suspension.
Adopt above-mentioned platelet suspension, platelet suspension after purification in batches adds dilution 20 times respectively, 40 times, DANHONG ZHUSHEYE solution after 80 times and aspirin (0.25mg/mL), using aspirin as positive control drug, common preincubate 10 minutes, it is subsequently adding ADP (25 ��Ms) as agonist, activate platelet so that it is assemble. Multi-functional plate reading machine is used to monitor instant OD value 30 minutes. OD value according to gained calculates hematoblastic instant aggregation rate, represents by average �� standard deviation (mean �� SD), n=3. * p < 0.01, compared with matched group. Result is as shown in Figure 1A.
Data result according to the measured variable concentrations DANHONG ZHUSHEYE antagonism ADP platelet aggregation caused, uses origin data processing software to be fitted curve, draws the medium effective concentration of DANHONG ZHUSHEYE. Result shows, DANHONG ZHUSHEYE can reach medium effective concentration, n=3 when diluting 30 times. Result is as shown in Figure 1B.
From the present embodiment it can be seen that under normal circumstances ADP can activate platelet, make platelet aggregation, but after adding the DANHONG ZHUSHEYE of different extension rate, the DANHONG ZHUSHEYE of most highly diluted multiple also can the effect of the obvious platelet aggregation that antagonism ADP causes. The DANHONG ZHUSHEYE of intermediate concentration has been able to reduce hematoblastic aggregation rate significantly. The DANHONG ZHUSHEYE of maximum concentration has reached the gathering suppression ratio of almost 50%.
Embodiment 2: the impact that in the platelet that ADP is caused by Radix Salviae Miltiorrhizae Flos Carthami extract, cAMP concentration reduces
The platelet suspension that use embodiment 1 prepares and dilution 20 times respectively, 40 times, DANHONG ZHUSHEYE solution preincubate (final volume is 150 microlitres) after 80 times adds 2mM calcium chloride, preincubate in constant temperature oscillator, constant temperature oscillator be set as 37 DEG C and 10 minutes 100 revs/min, be subsequently adding 20 ��Ms of ADP (final volume 200UL) and hatch 8 minutes. The HCl ELISA kit of the cAMP (provide) of isopyknic 0.1M is provided, then, the freezing of repetition and thawing 5 times, centrifugal use 1500g centrifugal force, continue 10 minutes. It is operated according to cAMP test kit (ELISA kit of cAMP, the production code member ADI-900-066) regulation of the concentrate measuring cAMP. Being separately added into ADP (20 ��Ms) in being added with the platelet suspension of DANHONG ZHUSHEYE solution of each concentration platelet is stimulated, then cAMP level has been measured, measurement result is shown in Fig. 2.
From figure 2 it can be seen that when DANHONG ZHUSHEYE dilutes 40 times, just can significantly demonstrate the antagonistic effect to ADP. Using adenyl cyclase activator Forskolin (10 ��Ms) as positive drug control. Measured value average �� standard deviation represents, n=3. Compared with matched group, * * p < 0.01; Compare with positive group, #p < 0.05, ##p < 0.01.
Embodiment 3: the impact of the effect that calcium ion concentration raises in the platelet that ADP is caused by Radix Salviae Miltiorrhizae Flos Carthami extract
The platelet suspension using embodiment 1 is centrifuged, and 200g centrifugal force continues 8 minutes. Supernatant discarded solution, re-uses Tyrodesbuffer (150mMNaCl, 3mMKCl, 1mMMgCl2,10mMHepes, 0.5mMdextrose, 0.1%BSA, PH7.4) Eddy diffusion platelet. Then, 10U/mlheparin, 0.2U/mlApyrase, 1 ��M of PGI it is sequentially added into2, static 8 minutes of room temperature. Then use above-mentioned steps again to rinse platelet, add 2.5mMprobenecid, 0.02%pluronic, 10 ��M of Fluo-3,0.5 ��M of PGI2, 0.02U/mlapyrase, then at preincubate in constant temperature oscillator, constant temperature oscillator be set as 37 DEG C and 30 minutes 100 revs/min. It is then respectively adding dilution 5 times, 10 times, the DANHONG ZHUSHEYE solution after 20 times, again hatch in constant temperature oscillator 15 minutes. It is subsequently adding 0.5 ��M of nPGI2, then rinse unconjugated dyestuff. Make platelet suspension again in Tyrodesbuffer, and be injected separately in 96 hole microtest plates, place them in [the Ca before measuring under room temperature2+] the flex pattern of i3, to hatching, being programmed of the fluorescence measurement of shifting liquid and calcium ion, the calcium chloride of 2mM and ADP are positioned in automatic sample groove. The platelet adding 10 ��Ms of Fluo-3 is placed on lucifuge place incubation 30 minutes, and then order adds 2mM calcium chloride and ADP (15 ��Ms). Per second carry out first order fluorescence mensuration. Microplate reader reads instant fluorescent value (A). Record the most imperial palace flow (B) of calcium ion simultaneously. Excitation wavelength 488nm, launches wavelength 525nm. Measured value average �� standard deviation represents, n=3. * p < 0.01, compared with matched group.
Fig. 3 is it is shown that DANHONG ZHUSHEYE can significantly reduce the effect that in the ADP platelet caused, calcium ion concentration raises. By detecting the radioimmunity aggregate amount (RFU) of calcium ion fluorescent, be can be seen that by Fig. 3 A, in platelet, calcium ion concentration is after adding ADP, change over and be obviously improved curve, and DANHONG ZHUSHEYE can the calcium ion concentration in the platelet that causes of ADP that reduce of dose dependent raise; Result display DANHONG ZHUSHEYE in Fig. 3 B can significantly reduce calcium ion concentration rise in the ADP platelet caused.
Embodiment 4: the Radix Salviae Miltiorrhizae Flos Carthami extract thrombolytic effect to arterial thrombus
The groin place, left side of postanesthetic rat is opened, expose downstream branch and the external iliac artery upstream of ventral aorta left-hand branch, adjusting green laser irradiation position, generating laser at a distance of 6cm according to modeling site, adjusts linear laser Doppler and carries out blood flow scanning. Tail vein injection bengal rose red. When modeling vascular flow quantitative change is 0 continue 10 seconds or after Continuous irradiation 90 minutes, it is believed that this blood vessel is blocked by thrombosis completely. Then DANHONG (low dosage 1.75ml/kg, middle dosage 5.25ml/kg, high dose 15.75ml/kg) injection or the heparin sodium heparin (2500U/kg) of tail vein injection various dose are started, altogether injection 7 days. Intercept modeling position blood vessel after 7 days, by vessel dissection under inverted microscope, carry out microscopic photography anatomic observation Intravascular Thrombus area (A). After various dose group thrombus area is added up, obtain residue thrombus area (B). Value average �� standard deviation represents, n=4. * p < 0.01, compared with matched group. Result is as shown in Figure 4.
Fig. 4 is it is shown that DANHONG ZHUSHEYE has obvious thrombolytic effect, and the DANHONG ZHUSHEYE of high dose even can remove endovascular thrombosis completely. By the treatment of DANHONG ZHUSHEYE, in rat aorta, thrombosis significantly reduces, and by the Danhong Injection in Treating of middle dosage (5.25ml/kg), in rat aorta, thrombosis is without obvious speckle, only the thread thrombosis of residual fraction; Through the Danhong Injection in Treating of too high dose (15.75ml/kg), thrombosis is without substantially residual.
Embodiment 5: the Radix Salviae Miltiorrhizae Flos Carthami extract impact on early stage dry gangrene
After the downstream branch place of the ventral aorta left-hand branch of rat causes arterial thrombus and makes its this place's blood flow completely plugged, cause artery occlusion, the situation that vein is unobstructed, cause that the symptom of early stage dry gangrene occurs in rat tails, start (the low dosage 1.75ml/kg of tail vein injection various dose, middle dosage 5.25ml/kg, high dose 15.75ml/kg) DANHONG ZHUSHEYE, altogether injection 7 days. Then the development of rat tails dry gangrene is observed. Result is as shown in Figure 5.
From figure 5 it can be seen that Radix Salviae Miltiorrhizae Flos Carthami extract can stop the development of the dry gangrene of early stage, and therapeutic effect to a certain extent can be reached. After causing thrombosis blocking blood vessel, treating as do not given DANHONG ZHUSHEYE, rat-tail tip there will be dry gangrene pathological changes in various degree; After the Danhong Injection in Treating of middle dosage (5.25ml/kg), rat-tail shows slight decortication and ulcer; After giving the DANHONG ZHUSHEYE of high dose (15.75ml/kg), rat-tail does not show any abnormal condition.
The various embodiments described above are for the Radix Salviae Miltiorrhizae Flos Carthami extract of DANHONG ZHUSHEYE, the new application of Radix Salviae Miltiorrhizae Flos Carthami extract is illustrated, it is understandable that, although embodiment 4 has simply investigated the Radix Salviae Miltiorrhizae Flos Carthami extract thrombolytic effect to arterial thrombus, but other thrombosis, such as phlebothrombosis, because it is identical with the formation mechenism of arterial thrombus, so arteries and veins thrombosis being had under the premise of thrombolytic effect at Radix Salviae Miltiorrhizae Flos Carthami extract, it is contemplated that the thrombosis that Radix Salviae Miltiorrhizae Flos Carthami extract is to other, for instance phlebothrombosises etc. also have thrombolytic effect.
In like manner, although embodiment 5 has simply investigated the Radix Salviae Miltiorrhizae Flos Carthami extract therapeutical effect to dry gangrene, but, other vascular thrombosis class disease, such as wet gangrene, diabetic foot etc., owing to being the disease caused by thrombosis, so being in that under the premise that Radix Salviae Miltiorrhizae Flos Carthami extract has the effect of thrombus dissolving, it is anticipated that these diseases are have certain therapeutical effect by Radix Salviae Miltiorrhizae Flos Carthami extract. In like manner, although embodiment 5 has simply investigated the therapeutical effect to dry gangrene of the medicine prepared by Radix Salviae Miltiorrhizae Flos Carthami extract, but, other vascular thrombosis class disease, such as wet gangrene, diabetic foot etc., owing to being the disease caused by thrombosis, so being in that under the premise that medicine prepared by Radix Salviae Miltiorrhizae Flos Carthami extract has the effect of thrombolytic, it is anticipated that these diseases are have certain therapeutical effect by Radix Salviae Miltiorrhizae Flos Carthami extract.
Claims (7)
1. Radix Salviae Miltiorrhizae Flos Carthami extract purposes in the medicine of preparation treatment and/or prevention vascular thrombosis class disease.
2. purposes as claimed in claim 1, it is characterised in that described vascular thrombosis class disease is the disease caused by arterial thrombus.
3. purposes as claimed in claim 2, it is characterised in that the described disease caused by arterial thrombus is the acral downright bad class disease caused by arterial thrombus.
4. purposes as claimed in claim 3, it is characterised in that the described disease caused by arterial thrombus is the dry gangrene caused by arterial thrombus.
5. purposes as claimed in claim 1, it is characterised in that described vascular thrombosis class disease is wet gangrene or diabetic foot.
6. purposes as described in any claim in Claims 1 to 5, it is characterised in that described Radix Salviae Miltiorrhizae Flos Carthami extract is in the one in tablet, capsule, soft capsule, pill, granule or injection.
7. purposes as claimed in claim 6, it is characterised in that described Radix Salviae Miltiorrhizae Flos Carthami extract is in the form of DANHONG ZHUSHEYE.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610087097.3A CN105616490A (en) | 2016-02-16 | 2016-02-16 | Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610087097.3A CN105616490A (en) | 2016-02-16 | 2016-02-16 | Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105616490A true CN105616490A (en) | 2016-06-01 |
Family
ID=56032110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610087097.3A Pending CN105616490A (en) | 2016-02-16 | 2016-02-16 | Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105616490A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582623A (en) * | 2017-09-08 | 2018-01-16 | 张勇 | Treat Chinese medicine composition of diabetic foot ulcer and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002828A (en) * | 2007-01-10 | 2007-07-25 | 厦门国宇知识产权研究有限公司 | Method for preparing Danhong injection, and products thereof |
| CN102772712A (en) * | 2012-08-22 | 2012-11-14 | 李佃场 | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot |
-
2016
- 2016-02-16 CN CN201610087097.3A patent/CN105616490A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002828A (en) * | 2007-01-10 | 2007-07-25 | 厦门国宇知识产权研究有限公司 | Method for preparing Danhong injection, and products thereof |
| CN102772712A (en) * | 2012-08-22 | 2012-11-14 | 李佃场 | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582623A (en) * | 2017-09-08 | 2018-01-16 | 张勇 | Treat Chinese medicine composition of diabetic foot ulcer and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Milani Júnior et al. | Snake bites by the jararacuçu (Bothrops jararacussu): clinicopathological studies of 29 proven cases in São Paulo State, Brazil. | |
| Vilas-Boas et al. | Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease | |
| US8962574B2 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| CN1121224C (en) | Pharmaceutical composition comprising compound having anti-Xa activity and platelet aggregation antagonist compound | |
| JP2005539006A (en) | Compositions for heart disease, methods for preparing the compositions, and uses thereof. | |
| US20100322870A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| US7384657B2 (en) | Composition of natural herb extract for treating cardiovascular disease and its method of preparation thereof | |
| CN1378472A (en) | Synergy between low molecular weight heparin and platelet aggregation inhibitor, providing combination therapy for prevention and treatment of various thromboembolic disorders | |
| CN101062086B (en) | Composite medicine for reducing blood fat and dissolving thrombus and its preparing process | |
| CN102526065B (en) | Compound injection preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| FR2491074A1 (en) | CHONDROITIN SULPHATE COMPLEX AND COMPLEXING AGENT | |
| RU2530645C2 (en) | Method of thrombosis treatment or prevention with application of dabigatran etexilate or its salt with improved efficiency in comparison with standard treatment with warfarin | |
| CN102548553B (en) | For treating the method and composition of diabetes ketoacidosis | |
| CN103405408B (en) | The application of chrysin in treatment ischemic cerebral apoplexy Chinese medicine | |
| CN105616490A (en) | Application of Radix salvia miltiorrhiza and Flos carthami extract in preparing medicine | |
| CN102114170B (en) | Traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury and preparation method thereof | |
| CN101297827B (en) | Medicament for curing coronary disease and coronary artery coating bracket coated therewith | |
| CN104083553B (en) | For preventing or treating the Chinese medicine extract of coronary heart disease, compositions and its production and use | |
| CN109369754A (en) | Nitrate compound and its application | |
| CN105902643A (en) | Drug for preventing thrombus formation and treating thrombus and preparation method thereof | |
| CN113116885A (en) | Application of tea polyphenol compounds in preparation of antithrombotic drugs | |
| CN107308146B (en) | Animal model of rat hypercoagulable state caused by tranexamic acid and construction method thereof | |
| US20070014882A1 (en) | Ellagic acid and anti-coagulant compound | |
| CN107982497A (en) | A kind of Traditional Chinese medicine compound composition for treating phlebothrombosis and its preparation and application | |
| CN103917544A (en) | Phased dosing of clopidogrel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |